Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233–40. https://doi.org/10.1016/j.coi.2009.03.002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gattinoni L, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907–12. https://doi.org/10.1084/jem.20050732.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anthony SM, Rivas SC, Colpitts SL, Howard ME, Stonier SW, Schluns KS. Inflammatory signals regulate IL-15 in response to lymphodepletion. J Immunol (Baltimore MD) 1950. 2016;196(11):4544–52. https://doi.org/10.4049/jimmunol.1600219.

Article  CAS  Google Scholar 

June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med. 2015;7(280):280ps7. https://doi.org/10.1126/scitranslmed.aaa3643.

Article  CAS  PubMed  Google Scholar 

Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318–21. https://doi.org/10.1126/science.3489291.

Article  CAS  PubMed  Google Scholar 

Marofi F, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12(1):81. https://doi.org/10.1186/s13287-020-02128-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klobuch S, Seijkens TTP, Schumacher TN, Haanen JBAG. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol. 2024;21(3):173–84. https://doi.org/10.1038/s41571-023-00848-w.

Article  CAS  PubMed  Google Scholar 

Ilyas S, Yang JC. Landscape of tumor antigens in T cell immunotherapy. J Immunol (Baltimore MD) 1950. 2015;195(11):5117–22. https://doi.org/10.4049/jimmunol.1501657.

Article  CAS  Google Scholar 

Huuhtanen J, et al. Evolution and modulation of antigen-specific T cell responses in melanoma patients. Nat Commun. 2022;13(1):5988. https://doi.org/10.1038/s41467-022-33720-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705–27.

PubMed  Google Scholar 

Clark WH, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81(24):1893–904. https://doi.org/10.1093/jnci/81.24.1893.

Article  PubMed  Google Scholar 

Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77(7):1303–10. https://doi.org/10.1002/(SICI)1097-0142(19960401)77:7%3c1303::AID-CNCR12%3e3.0.CO;2-5.

Article  CAS  PubMed  Google Scholar 

Azimi F, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678–83. https://doi.org/10.1200/JCO.2011.37.8539.

Article  PubMed  Google Scholar 

Mihm MC, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Investig J Tech Methods Pathol. 1996;74(1):43–7.

Google Scholar 

Lee N, Zakka LR, Mihm MC, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology (Phila). 2016;48(2):177–87. https://doi.org/10.1016/j.pathol.2015.12.006.

Article  Google Scholar 

Rosenberg SA, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–92. https://doi.org/10.1056/NEJM198512053132327.

Article  CAS  PubMed  Google Scholar 

Topalian SL, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol. 1988;6(5):839–53. https://doi.org/10.1200/JCO.1988.6.5.839.

Article  CAS  PubMed  Google Scholar 

Rosenberg SA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319(25):1676–80. https://doi.org/10.1056/NEJM198812223192527.

Article  CAS  PubMed  Google Scholar 

Rosenberg SA, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86(15):1159–66. https://doi.org/10.1093/jnci/86.15.1159.

Article  CAS  PubMed  Google Scholar 

Dudley ME, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 1997;25(3):243. https://doi.org/10.1097/01.CJI.0000016820.36510.89.

Article  Google Scholar 

Dudley ME, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233–9. https://doi.org/10.1200/JCO.2008.16.5449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenberg SA, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7. https://doi.org/10.1158/1078-0432.CCR-11-0116.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellebaek E, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients. J Transl Med. 2012;10(1):169. https://doi.org/10.1186/1479-5876-10-169.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pilon-Thomas S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012;35(8):615–20. https://doi.org/10.1097/CJI.0b013e31826e8f5f.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andersen R, et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res. 2016;22(15):3734–45. https://doi.org/10.1158/1078-0432.CCR-15-1879.

Article  CAS  PubMed  Google Scholar 

van den Berg JH, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer. 2020;8(2): e000848. https://doi.org/10.1136/jitc-2020-000848.

Article  PubMed  PubMed Central  Google Scholar 

Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. https://doi.org/10.1038/nature00766.

Article  CAS  PubMed  Google Scholar 

Atkins MB, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186–97. https://doi.org/10.1200/JCO.22.01763.

Article  CAS  PubMed  Google Scholar 

Larkin J, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2018;381(16):1535–46. https://doi.org/10.1056/NEJMoa1910836.

Article